Mike Stebbins | Sr. Vice President
Advanced Technology International
Dr. Stebbins is Senior Vice President of ATI and an accomplished executive dedicated to driving transformative outcomes in technology development and collaboration, particularly in health security, with a focus on national preparedness, response and recovery during public health emergencies and disasters. He brings extensive expertise in bridging the private sector with federal non-dilutive funding, having successfully facilitated over $12B in investments to foster innovation in the medical and health security fields.
Dr. Stebbins oversees ATI’s Medical and Health Security portfolio which includes five unique Other Transaction (OT) Agreement programs for HHS and DoD valued at greater than $60B which provides funding annually of more than $1B. The HHS portfolio includes BARDA’s Rapid Response Partnership Vehicle (RRPV) and BARDA’s Biopharmaceutical Manufacturing Preparedness – Consortium (BioMaP. On the DoD side the portfolio includes the Medical CBRN Defense Consortium (MCDC)) and the Countering Weapons of Mass Destruction Consortium (CWMD).
Dr. Stebbins has made significant contributions to national efforts, including supporting the rapid development and delivery of vaccines and treatments to address global health threats. He played a pivotal role in strengthening the U.S. industrial base and enhancing manufacturing capabilities to meet the nation’s advanced R&D and production needs. He led the creation of a $60B health security portfolio, consisting of five consortia, which has become a cornerstone for addressing federal health security challenges.
As a thought leader and ecosystem builder, Dr. Stebbins has engaged stakeholders across the medical and health security and other industrial base sectors over his career through keynote speaking, panel discussions and moderating events. He is committed to fostering organizational development and cultivating a growth mindset within teams to tackle the most pressing national security challenges.
Appearances:
Pre-Congress Workshops - Monday 30th March @ 10:00
BIODEFENSE & BIOSECURITY WORKSHOP
- ODEFENSE & BIOSECURITY (AM)Room 201Strategic priorities in domestic & international biodefense & biosecurity
- Strategic Priorities: Outlining the specific threats (e.g., emerging pathogens, select agents, or novel delivery systems) that are driving current policy and planning.
- Investment Areas: Identifying critical funding priorities for the next generation of medical countermeasures, platform technologies, and supply chain resilience.
- Technological Frontiers: Discussing promising new technologies, such as on-demand manufacturing, continuous fermentation for therapeutics, and advanced modeling/diagnostics, that are essential to achieving rapid response capabilities.Moderator: Vic Suarez, Founder and Principal Growth Partner, Blu Zone BioDr Mike Stebbins, Senior Vice President, ATI COL John Nuckols, PhD, JPM CPE-CBRN Medical *TBCMaj Gen(ret) Paul Friedrichs, MD, Senior Adviser, CSIS Global Health Policy CenterDr Kara Schmid, Director, Center for Military Psychiatry & Neuroscience, WRAIRDr Jean-Hu Primmer, Senior Director, Global Regulatory Strategy, Infectious Diseases, Moderna
11.30 – 12.30pm Panel: Redefining Preclinical Development: Non-clinical models to support development and licensure
- Transition from animal models
- Organ-on-a-Chip, In Silico Models & Regulatory Pathways
- Integration of new models into FDA submissions
- Implications for accelerated approvalModerator: Dr Bassam Hallis, Deputy Director, Head of Vaccine Development & Evaluation Centre, UKHSADr Girija Goyal, Principal Scientist, Advanced Technology Team, Wyss Institute Dr Ruth Cheng, CEO, ATCCDr Tom King, VP of Nonclinical R&D, Sabin Vaccine InstituteDr Javier Castillo-Olivares, Preclinical Lead – Coronavirus / Disease X, CEPI
BIODEFENSE & BIOSECURITY (PM)Room 2012pm Afternoon co-chair’s opening remarks: Taylor Sexton, Executive Director, Medical Countermeasures CoalitionDr Matthew Hepburn, Partner, Avinora Health
2:10 – 2.30pm Emerging tools and partnerships supporting outbreak response and biodefense *Title TBCDr Nahid Bhadelia, Founding Director, CEID; Founding Director, BEACON; Associate Professor, Infectious Diseases, Boston University Medical School
2:30 – 2:50pm Ensuring Assay Integrity: The Role of Authenticated Reference Data in BiodefenseJonathan Jacobs, Senior Director of Bioinformatics, ATCC
2:50 – 3:10pm Presentation TBC
3:10- 4:10pm Panel: Biosecurity & Bots: Setting the Guardrails for AI in Vaccine R&D
- Identifying and mitigating the risks of AI "hallucination" and erroneous data in vaccine research and development.
- Establishing oversight and accountability to safeguard AI tools, especially concerning drug safety and efficacy.
- The need for "AI police" or quality assurance to check code and validate AI outputs before they impact clinical trials.
- Discussing the challenge of moving away from manual expertise and the potential loss of human validation in pharmacovigilance and research.
- Examining the biosecurity implications of unregulated AI tools in creating novel molecules and designing preclinical models for vaccines.
- Forecasting Future Biothreats: Integrating AI and Global Surveillance.
- Exploring predictive analytics, AI-driven bio-surveillance, and early warning systems. Hansilla Alaigh, CEO & Founder, Global Action AllianceNikki Romanik, Co-Founder, BioRadar Public Benefit CompanyPatrick Boyle , Interim CSO, ATCC Dr Anne Cheever, Founder, Vela Scientific LLC
4:10pm End of Workshop
10:00 – 10:05 Opening RemarksWorkshop Co-Chairs: Taylor Sexton, Executive Director, Medical Countermeasures CoalitionDr Matthew Hepburn, Partner, Avinora Health
10:05– 10:30 Opening keynote TBC
10:30 – 11.30am Securing the Nation: Aligning U.S. Strategic Priorities, Investment, and Technology in Biodefense
Day 2 - Wednesday 1st April @ 12:10
Bridging the Gaps in our National Health Security, Aligning Federal Policy and Incentives
Despite major scientific and technological advances, persistent gaps in federal policy and incentives continue to limit the translation of innovation into scalable, reliable, and rapid-response health security capabilities. This session examines where current policy frameworks fall short—across research prioritization, procurement, and manufacturing sustainment—and how misaligned incentives undermine readiness between emergencies. This talk explores a range of policy options to institutionalize preparedness, strengthen coordination across the R&D and acquisition lifecycle for MCMs, and provide clearer signals that accelerate time-to-impact for vaccines and MCMs in the face of high-consequence biological threats.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events